Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Study (n=652 in US) reports majority had detectable antibody responses after second dose, although those without a response after first dose had generally low antibody levels; and poor humoral response was persistently linked to use of antimetabolite immunosuppression.

SPS commentary:

Overall, 98 (15%) had measurable antibody response after dose 1 and dose 2; 301 (46%) had no antibody response after dose 1 or dose 2; and 259 (39%) had no antibody response after dose 1 but subsequent antibody response after dose 2. The researchers note that although no threshold has been established for protective immunity, antibody levels were well below that which has been observed in immunocompetent vaccinees.

Journal of the American Medical Association